Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
about
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patientsTrial watch: Immunostimulatory cytokines in cancer therapy.Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II TrialAssociation of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma.Precision Oncology: Identifying Predictive Biomarkers for the Treatment of Metastatic Renal Cell CarcinomaClinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges.Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.Sunitinib side effects as surrogate biomarkers of efficacy.Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients.Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade.Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.Ramucirumab in metastatic renal cell carcinoma: The beginning or the end?An update on current management of advanced renal cell cancer, biomarkers, and future directions
P2860
Q33426958-EC05B66D-1388-40D5-B41E-77916DE64B22Q33880165-F2E85FBC-793F-4345-ADC7-01B3F3258E50Q34468729-9E7356C8-B430-44FD-8918-F7BA8E11110AQ35274936-C7540D5B-C051-4751-9A9F-E8BA55E73F33Q36116324-04AED03E-1D4C-4C76-A880-517F94A6B309Q36275134-85E413C1-1420-4067-B18F-464C098C4284Q36893510-04BCBC81-6D82-4932-89CA-F634E23F46A2Q37179808-F539338A-A68F-44C3-AC29-9A89139501F0Q37687194-6B88B413-8529-45FC-853B-27FC52B16624Q38334611-FE9A0AE2-5E5D-488E-8996-099EC3C8ACA2Q38402997-6C39F888-BE5C-4DE8-A1C3-9F0847CDB976Q38799848-473EEBC5-E4D6-4A67-917F-558E54F3F5B8Q39092937-063B782F-C07D-4C1B-BEC5-FFCFA4F709B9Q39235567-C4487192-E683-47D8-87DC-E79ACEE52457Q40177329-79FEF3F7-63F5-4FCA-B044-0CDACAF40D0AQ40986108-84DB6B6B-5CEA-4F22-AB2C-BFDF80287AFCQ41549055-4802DB4E-4144-405C-BA58-E3ACBA7ED353Q43100151-8776ED13-31A8-428C-89B9-7BF57124124AQ47605710-F6D47CA1-DF8B-4419-A7BF-80C8CB2BD51AQ56897121-38E230C5-BBC8-408F-B972-C60CF300CC91
P2860
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Circulating proteins as potent ...... tastatic renal cell carcinoma.
@en
Circulating proteins as potent ...... tastatic renal cell carcinoma.
@nl
type
label
Circulating proteins as potent ...... tastatic renal cell carcinoma.
@en
Circulating proteins as potent ...... tastatic renal cell carcinoma.
@nl
prefLabel
Circulating proteins as potent ...... tastatic renal cell carcinoma.
@en
Circulating proteins as potent ...... tastatic renal cell carcinoma.
@nl
P2093
P2860
P1476
Circulating proteins as potent ...... etastatic renal cell carcinoma
@en
P2093
Charles S Harmon
Gary R Hudes
J Andrew Williams
Robert A Figlin
Samuel E DePrimo
Sindy T Kim
Sylvie Négrier
Thomas E Hutson
P2860
P2888
P304
P356
10.1007/S00280-013-2333-4
P577
2013-11-13T00:00:00Z